close

Fenwick Represents Dexcom in Acquisition of TypeZero Technologies

August 23, 2018

Fenwick & West represented DexCom, Inc. (Nasdaq: DXCM), a leader in continuous glucose monitoring for people with diabetes, in its acquisition of TypeZero Technologies, Inc., which offers the inControl diabetes management system designed to provide personalized diabetes management solutions including technology to automatically adjust and regulate insulin. Financial terms of the transaction were not disclosed.

Dexcom’s acquisition of TypeZero follows a longstanding, productive relationship the two companies and the University of Virginia had in developing important technologies for diabetes management. Following the acquisition, Dexcom will carry the shared vision to improve the lives of people with diabetes through innovation. More information about Dexcom’s acquisition of TypeZero can be obtained from the company announcement.

The Fenwick transaction team included corporate lawyers Michael Brown, David Michaels, Victoria Lupu, Kate Dodson and Larry Suh; technology transactions lawyers Stefano Quintini, Spencer Glende and Pinar Bailey; executive compensation and employee benefits lawyers Scott Spector, Elizabeth Gartland and Laura McIntyre; and tax lawyers Will Skinner and Sergio Torres.​​